Response to Neoadjuvant Chemotherapy in Node-Positive Non-Inflammatory Breast Cancer
Association of Breast Surgery ePoster Library. Walsh S. 05/13/19; 257131; P087
Siún Walsh
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P087
Topic: Non surgical treatments
Background: Neo-adjuvant chemotherapy(NAC) has been increasingly used in recent years to downstage the breast cancer and nodal metastases, in order to facilitate breast conserving surgery(BCS) and avoid axillary lymph node dissection(ALND). Varying rates of response to NAC in the breast and axilla have been reported in the literature. We report response rates to NAC in a single Irish tertiary referral centre. Methods A retrospective review of patients with non-metastatic, node-positive breast cancer treated with NAC. Women with inflammatory breast cancer and bilateral disease were excluded. Clinical and pathological features were analysed, along with response to treatment. Results: The cohort comprised 105 women with a mean age of 48.8(25 - 78). 72(68.6%) underwent mastectomy and 32(30.5%) had BCS. Sentinel lymph node biopsy was performed in 11(10.5%), axillary sampling in 13(12.4%) and ALND in 81(77.1%). The majority of women had ER+/HER2- disease(41%). ER+/HER2+ disease was diagnosed in 23(21.9%), ER-/HER2+ in 19(18.1%) and triple negative breast cancer(TNBC) in 20(19%). Complete pathological response in the breast was seen in 19 patients(18.1%), and in the lymph nodes in 58(55.2%). The nodal response rate was 25.6% in those with ER+/HER2- disease, 65.2% for ER+/HER2+ disease, 52.6% for ER-/HER2+ disease and 55% for TNBC. ConclusionsThis data shows that NAC downstages the axilla of over half of patients presenting with node-positive, non-inflammatory, non-metastatic breast cancer. Nodal response rates are dependent on tumour subtype, and therefore patient selection is crucial.
Topic: Non surgical treatments
Background: Neo-adjuvant chemotherapy(NAC) has been increasingly used in recent years to downstage the breast cancer and nodal metastases, in order to facilitate breast conserving surgery(BCS) and avoid axillary lymph node dissection(ALND). Varying rates of response to NAC in the breast and axilla have been reported in the literature. We report response rates to NAC in a single Irish tertiary referral centre. Methods A retrospective review of patients with non-metastatic, node-positive breast cancer treated with NAC. Women with inflammatory breast cancer and bilateral disease were excluded. Clinical and pathological features were analysed, along with response to treatment. Results: The cohort comprised 105 women with a mean age of 48.8(25 - 78). 72(68.6%) underwent mastectomy and 32(30.5%) had BCS. Sentinel lymph node biopsy was performed in 11(10.5%), axillary sampling in 13(12.4%) and ALND in 81(77.1%). The majority of women had ER+/HER2- disease(41%). ER+/HER2+ disease was diagnosed in 23(21.9%), ER-/HER2+ in 19(18.1%) and triple negative breast cancer(TNBC) in 20(19%). Complete pathological response in the breast was seen in 19 patients(18.1%), and in the lymph nodes in 58(55.2%). The nodal response rate was 25.6% in those with ER+/HER2- disease, 65.2% for ER+/HER2+ disease, 52.6% for ER-/HER2+ disease and 55% for TNBC. ConclusionsThis data shows that NAC downstages the axilla of over half of patients presenting with node-positive, non-inflammatory, non-metastatic breast cancer. Nodal response rates are dependent on tumour subtype, and therefore patient selection is crucial.
P087
Topic: Non surgical treatments
Background: Neo-adjuvant chemotherapy(NAC) has been increasingly used in recent years to downstage the breast cancer and nodal metastases, in order to facilitate breast conserving surgery(BCS) and avoid axillary lymph node dissection(ALND). Varying rates of response to NAC in the breast and axilla have been reported in the literature. We report response rates to NAC in a single Irish tertiary referral centre. Methods A retrospective review of patients with non-metastatic, node-positive breast cancer treated with NAC. Women with inflammatory breast cancer and bilateral disease were excluded. Clinical and pathological features were analysed, along with response to treatment. Results: The cohort comprised 105 women with a mean age of 48.8(25 - 78). 72(68.6%) underwent mastectomy and 32(30.5%) had BCS. Sentinel lymph node biopsy was performed in 11(10.5%), axillary sampling in 13(12.4%) and ALND in 81(77.1%). The majority of women had ER+/HER2- disease(41%). ER+/HER2+ disease was diagnosed in 23(21.9%), ER-/HER2+ in 19(18.1%) and triple negative breast cancer(TNBC) in 20(19%). Complete pathological response in the breast was seen in 19 patients(18.1%), and in the lymph nodes in 58(55.2%). The nodal response rate was 25.6% in those with ER+/HER2- disease, 65.2% for ER+/HER2+ disease, 52.6% for ER-/HER2+ disease and 55% for TNBC. ConclusionsThis data shows that NAC downstages the axilla of over half of patients presenting with node-positive, non-inflammatory, non-metastatic breast cancer. Nodal response rates are dependent on tumour subtype, and therefore patient selection is crucial.
Topic: Non surgical treatments
Background: Neo-adjuvant chemotherapy(NAC) has been increasingly used in recent years to downstage the breast cancer and nodal metastases, in order to facilitate breast conserving surgery(BCS) and avoid axillary lymph node dissection(ALND). Varying rates of response to NAC in the breast and axilla have been reported in the literature. We report response rates to NAC in a single Irish tertiary referral centre. Methods A retrospective review of patients with non-metastatic, node-positive breast cancer treated with NAC. Women with inflammatory breast cancer and bilateral disease were excluded. Clinical and pathological features were analysed, along with response to treatment. Results: The cohort comprised 105 women with a mean age of 48.8(25 - 78). 72(68.6%) underwent mastectomy and 32(30.5%) had BCS. Sentinel lymph node biopsy was performed in 11(10.5%), axillary sampling in 13(12.4%) and ALND in 81(77.1%). The majority of women had ER+/HER2- disease(41%). ER+/HER2+ disease was diagnosed in 23(21.9%), ER-/HER2+ in 19(18.1%) and triple negative breast cancer(TNBC) in 20(19%). Complete pathological response in the breast was seen in 19 patients(18.1%), and in the lymph nodes in 58(55.2%). The nodal response rate was 25.6% in those with ER+/HER2- disease, 65.2% for ER+/HER2+ disease, 52.6% for ER-/HER2+ disease and 55% for TNBC. ConclusionsThis data shows that NAC downstages the axilla of over half of patients presenting with node-positive, non-inflammatory, non-metastatic breast cancer. Nodal response rates are dependent on tumour subtype, and therefore patient selection is crucial.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}